Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944).

ABSTRACT:

Background

With increasing concerns about the impact of frequent antibiotic usage on the human microbiome, it is important to characterize the potential for such effects in early antibiotic drug development clinical trials. In a randomised Phase 2a clinical trial study that evaluated the pharmacokinetics of repeated oral doses of gepotidacin, a first-in-chemical-class triazaacenaphthylene antibiotic with a distinct mechanism of action, in adult females with uncomplicated urinary tract infections for gepotidacin (GSK2140944) we evaluated the potential changes in microbiome composition across multiple time points and body-sites ( ClinicalTrials.gov : NCT03568942).

Results

Samples of gastrointestinal tract (GIT), pharyngeal cavity and vaginal microbiota were collected with cons

SUBMITTER: Nuzzo A 

PROVIDER: S-EPMC8207760 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature